Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Andrew McGarry, Karl Kieburtz, Corneliu Luca et al.|The Lancet Neurology|2023

Cited by 128